BVS•benzinga•
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
Summary
Bioventus posted strong Q4 results, with EPS and revenue surpassing estimates. The company projects 2025 sales of $560M–$570M and adjusted EPS of $0.64–$0.68.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 11, 2025 by benzinga